Cargando…

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status

BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kortekaas, Kim E., Santegoets, Saskia J., Abdulrahman, Ziena, van Ham, Vanessa J., van der Tol, Marij, Ehsan, Ilina, van Doorn, Helena C., Bosse, Tjalling, van Poelgeest, Mariëtte I. E., van der Burg, Sjoerd H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724316/
https://www.ncbi.nlm.nih.gov/pubmed/31481117
http://dx.doi.org/10.1186/s40425-019-0712-z
_version_ 1783448965905121280
author Kortekaas, Kim E.
Santegoets, Saskia J.
Abdulrahman, Ziena
van Ham, Vanessa J.
van der Tol, Marij
Ehsan, Ilina
van Doorn, Helena C.
Bosse, Tjalling
van Poelgeest, Mariëtte I. E.
van der Burg, Sjoerd H.
author_facet Kortekaas, Kim E.
Santegoets, Saskia J.
Abdulrahman, Ziena
van Ham, Vanessa J.
van der Tol, Marij
Ehsan, Ilina
van Doorn, Helena C.
Bosse, Tjalling
van Poelgeest, Mariëtte I. E.
van der Burg, Sjoerd H.
author_sort Kortekaas, Kim E.
collection PubMed
description BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome, an in-depth study of the tumor immune microenvironment was performed. METHODS: Sixty-five patients with invasive VSCC matched for age, FIGO stage and treatment modality, were grouped according to the presence of HPV and p53 protein expression status. Archived tissues were analyzed for intraepithelial and stromal expression of CD3, CD8, Foxp3, PD-1, and pan-keratin in randomly selected areas using immunofluorescence. Additional phenotyping of T cells was performed ex-vivo on VSCC (n = 14) and blood samples by flow cytometry. Healthy vulvar samples and blood served as controls. RESULTS: Based on T-cell infiltration patterns about half of the VSCC were classified as inflamed or altered-excluded while one-third was immune-deserted. High intraepithelial helper T cell infiltration was observed in 78% of the HPV-induced VSCC, 60% of the HPVnegVSCC/p53wildtype and 40% of the HPVnegVSCC with abnormal p53 expression. A high intraepithelial infiltration with activated (CD3(+)PD-1(+)), specifically helper T cells (CD3(+)CD8(−)Foxp3(−)), was associated with a longer recurrence-free period and overall survival, irrespective of HPV and p53 status. Flow cytometry confirmed the tumor-specific presence of activated (CD4(+)PD-1(++)CD161(−)CD38(+)HLA-DR(+) and CD8(+)CD103(+)CD161(−)NKG2A(+/−)PD1(++)CD38(++)HLA-DR(+)) effector memory T cells. CONCLUSION: This is the first study demonstrating an association between intraepithelial T cells and clinical outcome in VSCC. Our data suggest that abnormal p53 expressing VSCCs mostly are cold tumors whereas HPV-driven VSCCs are strongly T-cell infiltrated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0712-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6724316
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67243162019-09-10 High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status Kortekaas, Kim E. Santegoets, Saskia J. Abdulrahman, Ziena van Ham, Vanessa J. van der Tol, Marij Ehsan, Ilina van Doorn, Helena C. Bosse, Tjalling van Poelgeest, Mariëtte I. E. van der Burg, Sjoerd H. J Immunother Cancer Research Article BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome, an in-depth study of the tumor immune microenvironment was performed. METHODS: Sixty-five patients with invasive VSCC matched for age, FIGO stage and treatment modality, were grouped according to the presence of HPV and p53 protein expression status. Archived tissues were analyzed for intraepithelial and stromal expression of CD3, CD8, Foxp3, PD-1, and pan-keratin in randomly selected areas using immunofluorescence. Additional phenotyping of T cells was performed ex-vivo on VSCC (n = 14) and blood samples by flow cytometry. Healthy vulvar samples and blood served as controls. RESULTS: Based on T-cell infiltration patterns about half of the VSCC were classified as inflamed or altered-excluded while one-third was immune-deserted. High intraepithelial helper T cell infiltration was observed in 78% of the HPV-induced VSCC, 60% of the HPVnegVSCC/p53wildtype and 40% of the HPVnegVSCC with abnormal p53 expression. A high intraepithelial infiltration with activated (CD3(+)PD-1(+)), specifically helper T cells (CD3(+)CD8(−)Foxp3(−)), was associated with a longer recurrence-free period and overall survival, irrespective of HPV and p53 status. Flow cytometry confirmed the tumor-specific presence of activated (CD4(+)PD-1(++)CD161(−)CD38(+)HLA-DR(+) and CD8(+)CD103(+)CD161(−)NKG2A(+/−)PD1(++)CD38(++)HLA-DR(+)) effector memory T cells. CONCLUSION: This is the first study demonstrating an association between intraepithelial T cells and clinical outcome in VSCC. Our data suggest that abnormal p53 expressing VSCCs mostly are cold tumors whereas HPV-driven VSCCs are strongly T-cell infiltrated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0712-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-03 /pmc/articles/PMC6724316/ /pubmed/31481117 http://dx.doi.org/10.1186/s40425-019-0712-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kortekaas, Kim E.
Santegoets, Saskia J.
Abdulrahman, Ziena
van Ham, Vanessa J.
van der Tol, Marij
Ehsan, Ilina
van Doorn, Helena C.
Bosse, Tjalling
van Poelgeest, Mariëtte I. E.
van der Burg, Sjoerd H.
High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title_full High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title_fullStr High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title_full_unstemmed High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title_short High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
title_sort high numbers of activated helper t cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of hpv or p53 status
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724316/
https://www.ncbi.nlm.nih.gov/pubmed/31481117
http://dx.doi.org/10.1186/s40425-019-0712-z
work_keys_str_mv AT kortekaaskime highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT santegoetssaskiaj highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT abdulrahmanziena highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT vanhamvanessaj highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT vandertolmarij highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT ehsanilina highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT vandoornhelenac highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT bossetjalling highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT vanpoelgeestmarietteie highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status
AT vanderburgsjoerdh highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status